Beyond Glycemic Control: Concurrent GLP-1 Receptor Agonist Use Is Associated with Reduced Urinary Adverse Events Following OnabotulinumtoxinA Treatment in Non-Diabetic Adults with Overactive Bladder.

Muhammed A M Hammad, Sophia G Quesada, Aimee L Belczyk, Gamal M Ghoniem

Registry-linked trialAbstract read

In one paragraph

Article in Toxins, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It reports registered trial NCT07513168. Cited by 2 papers.

0numbers the graph read from it

0cells of the map it votes in

2citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07513168 phase4recruiting

Efficacy and Safety of Low-Dose Semaglutide for Weight Loss and Cardiometabolic Improvement in Obese Pakistani Adults Without Type 2 Diabetes: A Single-Arm Open-Label Single-Center Trial

Ran2025Enrolled60Registered outcomes6Posted comparisons0ConditionsCardiometabolic Risk Factors, Obesity, Weight ReductionArmsLocally available low-dose semaglutide (0.25 mg, 0.5 mg, 1 mg)

PMID 33755728 PMID 33625476 PMID 38679221 PMID 36216945 PMID 33977495 PMID 40804463 PMID 31689026 PMID 34706925 PMID 34942372 PMID 35441470 PMID 40978842 PMID 36254579other papers from this trial

Open the trial in the graph

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

Effects of GLP-1 analogs on metabolic alterations including male sexual function, hypogonadism and erectile dysfunction: a narrative review.Translational andrology and urology · 2026
Review
Beyond weight loss: Effect of GLP-1 receptor agonist therapy on the urological health.Urology case reports · 2026
Article

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Muhammed A M HammadDepartment of Urology, University of California Irvine, Orange, CA 92868, USA.ORCID 0000-0001-5396-1364

Sophia G QuesadaDepartment of Urology, University of California Irvine, Orange, CA 92868, USA.

Aimee L BelczykDepartment of Urology, University of California Irvine, Orange, CA 92868, USA.ORCID 0009-0002-1998-9894

Gamal M GhoniemDepartment of Urology, University of California Irvine, Orange, CA 92868, USA.ORCID 0000-0002-9028-7783

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Semaglutide, a GLP-1 (glucagon-like peptide-1) receptor agonist, is widely prescribed for weight loss in non-diabetic populations. Given the link between obesity and overactive bladder (OAB), we explored whether GLP-1 use would improve adverse urinary events beyond its weight loss benefit for non-diabetic adults undergoing onabotulinumtoxin A (BTX-A) treatment for OAB. Using the TriNetX database, we conducted a retrospective cohort study of non-diabetic OAB patients treated with BTX-A alone or with concurrent GLP-1 therapy. Propensity score matching (1:1) was adjusted for age, race, ethnicity, hypertension, and BMI/obesity. After matching, 992 patients were included in each group. GLP-1 use was associated with a lower incidence of urinary retention (8.6% vs. 4.9%, risk difference 3.66%,

Indexed as

Botulinum Toxins, Type AGlucagon-Like Peptide-1 Receptor AgonistsUrinary Bladder, OveractiveAdultAgedFemaleGlucagon-Like Peptide 1Glucagon-Like PeptidesGlycemic ControlHumansMaleMiddle AgedRetrospective StudiesSemaglutideUrinary RetentionUrinary Tract InfectionsBotulinum Toxins, Type AGlucagon-Like Peptide 1Glucagon-Like Peptide-1 Receptor AgonistsGlucagon-Like Peptidesonabotulinum toxin ASemaglutidediabetesGLP-1 receptor agonistonabotulinumtoxin Aoveractive bladder (OAB)semaglutideurinary retentionweight loss

Identifiers

PMID41295856

DOI10.3390/toxins17110542

PMCPMC12656553

What Socratic holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

NCT07513168ClinicalTrials.gov

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.